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Since the first descriptions of acquired immune deficiency 
syndrome (AIDS) in homosexual men in San Francisco in 
1981, HIV has commonly been associated with and implicat-
ed in the pathogenesis of vascular disease. The South African 
experience of HIV-related aneurysms occurring in young 
HIV-infected individuals suggested a distinct clinicopatho-
logical entity, based on distribution, morphological descrip-
tion and histopathological findings.1,2
Less convincing, but occurring more frequently in younger 
HIV-infected South Africans, has been an apparently unique 
type of vascular occlusive disease.3 This has generally been 
encountered in those individuals with advanced disease and 
significant immunocompromise. These manifestations are 
not unique to South Africa, and have also been described 
elsewhere.4  
Although many reports preceded the highly active anti-
retroviral treatment (HAART) era, they still occur in areas 
where HAART is not available. Very few descriptions of HIV-
associated vasculopathy in other sites, such as the cerebral, 
coronary, renal or mesenteric territories, have been reported 
in the surgical literature. This is understandable, considering 
that much of the pathology manifests as systemic vasculitides, 
with very limited surgical treatment options. Systemic vascu-
litides, however, have been reported in less than 1% of HIV 
patients, predominantly affecting skin, muscle and nerves 
and very rarely other organ systems. 
The advent of HAART has dramatically modified out-
comes in HIV/AIDS, with concerns now being expressed 
about the older HIV population group exposed to long-term 
HAART now being more susceptible to precocious and/or 
accelerated atherosclerotic vascular disease.
The aetiology of vasculopathy in HIV-infected individuals 
has been widely debated, and is probably multifactorial. For 
practical purposes HIV vasculopathy may be classified as:
• HIV-related vasculitis
• HIV/HAART-related atherosclerotic vascular disease
• mixed (both pathologies occurring in the same patient).
HIV-related vasculitis can further be subclassified into four 
types:5 
Type I: Vasculitides that are well described in the non-HIV 
population group but occur coincidentally in HIV-infected 
individuals (Takayasu’s disease, Behçet’s disease, giant cell 
arteritis, polyarteritis nodosa, etc.).
Type II: Drug-associated vasculitis (abacavir, nevirapine, 
effavirenz, trimethoprim/sulphamethoxazole, etc.).
Type III: Vasculitis-associated with known infections (cyto-
megalovirus, hepatitis B, hepatitis C, Toxoplasma gondii, etc.).
Type IV: Vasculitis probably associated with HIV aetiology 
(primary angiitis of the central nervous system (CNS), 
Kawasaki-like syndromes, non-hepatitis B polyarteritis 
nodosa, HIV-related aneurysms, etc.).
Cerebrovascular disease
HIV and stroke
Neurological disorders are not uncommon in patients 
with HIV-1 infection. Postmortem studies have shown that 
involvement of the CNS is estimated to occur in between 
70% and 90% of HIV-infected patients. Approximately 10 
- 20% of HIV-infected patients present with neurological 
symptoms as a first manifestation.6,7 
Multiple pathologies contribute to the aetiology of stroke 
in HIV-1-infected patients. The vast majority are associated 
with CNS infections and/or tumours. Only a small propor-
tion are related to vascular pathology directly attributable to 
or associated with the HIV infection itself.8 
Overall, clinical neurological manifestations occur in up to 
40% of patients with AIDS, but stroke is thought to occur 
in as few as 1.3% of cases, although the true incidence of 
stroke in HIV patients is not accurately known. HIV-positive 
patients with strokes generally have a poor survival (mean of 
~4 months). 
Cerebral infarction rates range from 6% to 34% in autopsy 
series, but few have clinical correlation. In one review of 6 
clinical series, the stroke prevalence ranged from 0.5% to 
34%.9 A cohort study of 772 HIV-positive patients reported 
a 0.8% prevalence for transient ischaemic attacks (TIA) and 
1.2% for stroke, with an estimated annual incidence rate of 
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Summary
Descriptions of the numerous manifestations of human 
immunodeficiency virus (HIV) infection affecting almost every 
organ system have abounded in recent publications. Multiple 
radiological, clinical and postmortem reports have recorded 
the cerebral, pulmonary, cardiac, renal, rheumatological and 
gastrointestinal pathologies in HIV-infected individuals, ranging 
from the bizarre to the mundane. Large-vessel HIV-related 
vascular manifestations have previously been reported in the 
surgical literature. We describe and review the manifestations 
of HIV-associated vasculopathy as it pertains to the cerebral, 
cardiovascular, mesenteric and renal circulations.
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216 per 100 000. The prevalence was highest in the more 
advanced form of the disease.10
In another clinical review of 1 600 HIV patients, Pinto 
found an incidence of 0.75%, which was higher than the risk 
of stroke in a comparable HIV-negative group (0.025%). In 
an autopsy review of 763 patients only 1.3% of HIV-infected 
patients had a stroke syndrome. Pathologically detected isch-
aemic infarcts were more common (68%).7 
Connor et al., in an autopsy study excluding other aeti-
ologies associated with stroke in HIV-positive cases, found 
only 1 TIA recorded clinically in 10 cases (of a total of 183 
autopsies) with cerebral infarcts directly attributable to HIV 
vasculopathy.11
Numerous autopsy, radiological and clinical studies sug-
gest an association between stroke and HIV infection related 
to vascular pathologies, coagulopathies or cardio-embolism. 
HIV-related vasculopathy has generally been described in 
association with co-infections in HIV-infected patients. 
In a recent study, Mochan et al. analysed 35 HIV, HAART-
naïve patients with stroke using CT imaging.12 They found 
cerebral infarction in 33 (94%) and intracerebral haemor-
rhage in 2 (6%). In 31 patients the infarcts occurred in the 
distribution of the anterior circulation. Conventional cerebral 
angiography, performed in 22 patients, was normal in 15. 
The seven patients revealed: arterial thrombosis in 3 patients 
(internal carotid artery in 2, middle cerebral artery in 1, dif-
fuse intracranial vasculopathy with multiple stenotic lesions 
involving small and medium-size vessels in 2 cases, low-grade 
carotid bifurcation stenosis in 1 case, and extracranial inter-
nal carotid artery dissection in 1 case. In their analysis, 10 
patients had more than 1 underlying cause for the stroke, 
including meningitis (25%), potential cardioembolic cause 
(9%), coagulopathy (49%) and hypertension (2 patients). 
Only 4 patients had a stroke directly attributable to HIV-
related vasculopathy or vasculitis (with varicella zoster co-
infection in 1 case).
HIV-related cerebral vasculitis has generally been associ-
ated with CNS infections, lymphoproliferative disorders or 
drugs.
There are 2 South African retrospective, case-controlled 
studies comparing stroke rates in young patients (age 
under 46 years). Hoffman et al. compared 22 HIV-positive, 
HAART-naïve, stroke patients with 22 HIV-negative con-
trols with stroke.13 The distributions of infarcts were similar 
in both groups on CT or MR imaging and micro-infarcts 
were not documented in either group. Conventional angi-
ography (not done in all cases) demonstrated more internal 
carotid artery and middle cerebral artery occlusions in the 
HIV group than in the control group. Classic risk factors for 
stroke were infrequent in the HIV group. Patel et al. reviewed 
293 black patients aged between 15 and 44 years with stroke 
(245 cerebral infarctions and 48 haemorrhages).14 There 
were 56 HIV-positive, HAART-naïve patients (51 with cere-
bral infarction and 5 with cerebral haemorrhage). No spe-
cific aetiology was found in 68.9% of the cases. There was 
no difference in cardioembolic aetiology between the groups. 
Conventional angiograms were performed in 158 patients, 
of which 62% were positive. There was no statistical differ-
ence in the number of internal carotid artery (ICA) or mid-
dle cerebral artery (MCA) occlusions between the groups, 
although there was a trend towards more ICA and MCA 
occlusions in the HIV group.
Tipping et al. reviewed 67 HIV-positive patients (of which 
61 patients were under 45 years of age).15 Cerebral infarction 
occurred in 96% (64 patients) and intracerebral haemorrhage 
in 4%. HIV-positive patients did not have classic risk factors 
for stroke. A distinct aetiology for stroke was identified in 
81% of patients: infections (28%), coagulopathy (19%), 
cardioembolism (14%), unknown (19%) and HIV-associ-
ated vasculopathy (20%). Occlusion of the common carotid 
artery (CCA) or ICA was demonstrated in 7 (11%) patients. 
Autopsy findings in 1 patient revealed thrombotic occlusion 
of the right carotid artery. Sections of the carotid bifurcation 
revealed adventitial fibrosis and neovascularisation, intimal 
fibrosis, fragmentation of the internal elastic lamina, medial 
degeneration and lymphoplasmacytic infiltrate. Six patients 
(9%) had intracranial vascular pathology not associated with 
any other aetiology for stroke. Angiography revealed medium 
vessel occlusion, with or without ectasia, and areas of vascu-
lar stenoses involving the circle of Willis and cerebral arteries 
including their proximal divisions.
In the Edinburgh HIV autopsy cohort, 10 cerebral infarcts 
(of a total of 183 cases with cerebral infarcts) were ascribed to 
HIV vasculopathy.11  Histopathology of the intracranial ves-
sels revealed intimal thickening, dilatation of the perivascular 
spaces with areas of pigment deposition, microvessel miner-
alisation and perivascular inflammatory cells. Interestingly, 
no vasculitis (arterial wall inflammatory infiltrate) was found. 
The authors suggest an exhaustive search for stroke aetiology 
before ascribing it to HIV vasculopathy.
Many of the studies evaluated stroke in HIV-positive 
patients not receiving HAART. In a recent study, Ortiz et 
al. evaluated 82 HIV-positive patients.16 Forty-eight patients 
(58%) were on HAART. Seventy-five patients (92%) had a 
diagnosis of HIV prior to the stroke. Among the 77 patients 
who had ischaemic strokes, 10 had atherosclerosis involv-
ing large arteries (4 CCA/ICA, 5 MCA and 1 vertebro-
basilar stenoses). Fifteen patients (19%) had small-vessel 
occlusion confirmed on imaging studies. Other aetiologies 
included vasculitis in 10 (23%), vertebral artery dissection 
in 1, coagulopathy in 7 and a potential cardioembolic source 
in 15. Classic risk factors were present: tobacco smoking 
(51%), hypertension (42%) and diabetes mellitus (7%). 
Interestingly, hyperlipidaemia was uncommon. Patients with 
atherothrombotic strokes were older (45.3 versus 40.1 mean 
age) than those with non-atherothrombotic strokes. Sixty-
eight per cent of patients with atherothrombotic strokes had 
received HAART. However, the use of HAART did not cor-
relate with the type of ischaemic stroke.
Stroke due to co-viral vasculitis in HIV-positive patients 
has been described. These patients usually present with 
advanced HIV infection. Varicella zoster vasculitis (VZV) 
associated with stroke has been described following zoster 
ophthalmicus and zoster oticus. Zoster vasculitis is a granu-
lomatous vasculitis with multinucleate giant cells, viral anti-
gens, viral DNA and Cowdry A inclusions seen in arterial 
walls. Diagnosis is usually accomplished by lumbar puncture 
with cerebrospinal fluid (CSF) analysis and serology. Ortiz 
et al. described a case associated with the Ramsay Hunt 
syndrome in which MRI demonstrated a pontine infarct.17 
There were multiple stenotic areas involving distal vertebral 
and basilar arteries, as well as the arteries related to the circle 
of Willis on MRI and conventional angiography. Treatment 
consists of gancyclovir, prednisone and HAART.
Primary angiitis of the CNS (PACNS), first described in 
1959, is an uncommon vasculitis predominantly involving 
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small and medium intracerebral arteries and veins, including 
leptomeningeal vessels.18,19 It may be associated with immu-
nocompromise, and has been documented in HIV-infected 
patients with stroke. Diagnosis is based on neuroimaging, 
CSF analysis, and exclusion of current infection and other 
CNS pathology on screening. Nogueras et al. reported a case 
of recurrent strokes with primary angiitis of the CNS in an 
HIV-infected patient.19 MRA findings of segmental stenoses 
involving the distal ICA and basilar arteries were docu-
mented, with marked luminal narrowing. Histopathological 
findings documented lymphocytic vasculitis of the basal 
meningeal and parenchymal vessels. A fibrous vasculitis was 
found in vessels of the circle of Willis with intimal fibrosis, 
medial destruction and lymphoplasmacytic infiltrate with 
multinucleated giant cells. PACNS generally had a poor 
prognosis, most cases being reported in autopsy series. 
Whether HAART will alter the incidence or prognosis with 
PACNS remains speculative.
Stroke secondary to spontaneous artery dissection in HIV-
infected patients has been reported.12,16 Felicio et al. reported 
a case in an HIV-infected patient with Wallenberg’s syndrome 
(ipsilateral cerebellar infarct) secondary to a vertebral artery 
dissection.20 The patient was anticoagulated with document-
ed neurological improvement.
Stroke secondary to CCA/ICA atherosclerotic plaques has 
been well studied in HIV-negative patients. Carotid endar-
terectomy and carotid angioplasty with stenting, both cur-
rently indicated in treating significant carotid stenoses, have 
played a major role in reducing stroke. Studies have indicated 
an increasing incidence of cardiovascular and cerebrovas-
cular disease in the HAART era. Currently there does not 
appear to be an increasing incidence of stroke associated with 
carotid bifurcation plaques in HIV-infected patients in the 
HAART era. Regina et al. reported 2 patients with asymp-
tomatic high-grade ICA stenosis of approximately 80%, 
with carotid duplex showing progressive stenosis in both 
patients.21 Both CCA and external carotid arteries (ECA) 
were normal. Both were young patients (<40 years). Both 
were on long-standing HAART including a protease inhibi-
tor (PI). At surgery, both the lesions were found to be focal, 
thick,  fibrotic ICA plaques with no endarterectomy plane. 
A resection of the proximal ICA with reimplantation to the 
ECA was performed in both. Histology revealed an intimal 
lesion with fibro-fatty plaque, fragmentation of the internal 
elastic lamina, medial scarring and occasional perivascular 
lymphocytes around the vasa vasorum. A lymphoplasmacytic 
infiltrate was found in the intima and media. HIV-1 was iso-
lated from biopsy specimens.
HIV and cerebral aneurysms
HIV-related intracranial aneurysms have been described 
in paediatric22-24 and, more recently, adult populations. 
Dubrovsky et al. reported on 5 paediatric cases and reviewed 
an additional eight paediatric cases from the literature.25 
Seven patients acquired the HIV infection perinatally. 
Postmortem findings were described in 4 patients. All had 
ectasia and aneurysms confined to the large arteries of the 
circle of Willis. The consistent histological findings were 
intimal thickening, destruction of the internal elastic lamina, 
loss of muscularis and medial fibrosis. The latency period to 
diagnosis ranged from 2 years to 11 years, with poor survival 
following diagnosis (mean <6 months). They postulated VZV 
infection and HIV as possible aetiological agents. HIV pro-
tein and genome was isolated in 2 of the postmortem cases.
Patsalides et al. reviewed 426 HIV-positive paediatric 
patients, who all had neuroimaging studies.22 Eleven patients 
(2.6%), 6 of whom were males, were found to have cerebro-
vascular lesions. Seven patients had no neurological symp-
toms and only 1 had a stroke. Vertical transmission of the 
HIV infection occurred in 7 patients. Multiple aneurysms 
(total of 26 aneurysms) were documented in 7 patients, 4 
with associated cerebral infarcts. Twenty aneurysms involved 
the anterior circulation. Twenty-four aneurysms were fusi-
form. Four of the 7 patients had multiple aneurysms. Twenty-
seven cerebral infarcts were seen in 8 patients, 4 without 
aneurysms. Seven cerebral infarcts were cortical and 20 
involved the basal ganglia, 16 infarcts occurring in territories 
supplied by arteries associated with aneurysms. Co-infec-
tion with VZV was seen in 45% (5/11). All patients had 
advanced HIV disease (CD4 counts less than 200 cells/µl) 
Histopathological findings in 1 patient were similar to those 
reported by Dubrovsky et al.
HIV-related cerebral aneurysms complicated by symp-
tomatic ischaemic infarcts have been described as part of 
the immune-reconstitution inflammatory syndrome (IRIS).23 
An immune-mediated vasculitis is thought to be the basis 
of IRIS in response to improved immunocompetence with 
HAART, generally after less than 1 year of therapy. MRA in 
this case revealed multiple fusiform aneurysms involving the 
circle of Willis. No other aetiology was found on screening. 
The patient improved on HAART, acyclovir and aspirin.
Cerebral vasculopathy with aneurysm formation has also 
been described in young HIV-positive adults.26-28 Kossorotoff 
et al. described 2 HIV-positive patients with strokes and 
MCA territory infarcts.26 MRA revealed multiple fusiform 
aneurysms, ectasia and stenotic areas involving small and 
medium-sized arteries. One patient had an ipsilateral throm-
bosed distal ICA aneurysm. VZV was probably causally 
related in 1 patient. 
Tipping et al. described stroke in a 27-year-old female 
patient with neuroimaging findings of fusiform aneurysmal 
dilatation of the arteries of the circle of Willis.27 Autopsy find-
ings revealed fusiform dilatation of left ICA, and left MCA 
branches. Thrombus was present in the MCA and anterior 
divisions. Histology of the involved segments revealed intimal 
fibrosis with hyalinisation, medial atrophy and fragmentation 
of the elastic lamina. Alcian blue staining showed depositions 
of mucopolysaccharides in the intima and media. 
Subarachnoid haemorrhage (SAH) has been described in 
association with HIV-related cerebral aneurysms in adults. 
Hamilton et al. reported a 34-year-old HIV-positive male 
on HAART (CD4 count 66 cells/µl) with end-stage renal 
failure, cardiomyopathy and left-sided weakness.29 CTA 
demonstrated an SAH with multiple fusiform and giant 
saccular aneurysms. He was treated expectantly. Taylor et 
al. reported 3 patients with SAH and cerebral aneurysms 
in young HIV-infected adults with low CD4 counts.30 They 
postulated intracranial arterial dissection as the pathogenic 
process associated with SAH in 2 of their patients. Two of 
the patients were treated with endovascular techniques: 
segmental vessel trapping using GDC coils in 1 patient and 
partial coil embolisation of a false aneurysm in the other 
(Figs 1 and 2).
Modi et al. recently reported 3 cases of HIV-related intra-
cranial aneurysms presenting with cognitive impairment, 
SAH and seizures respectively.31 All had multiple fusiform 
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intracranial aneurysms (1 patient thought to have a saccular 
aneurysm was found to have a fusiform aneurysm at surgery 
and was not treated). A screen for other aetiology was nega-
tive in all 3 cases. On review of the literature, they discovered 
an additional 11 patients presenting with strokes, headache 
and SAH, 7 of whom had saccular (probably congenital) 
aneurysms, with the remainder being fusiform aneurysms.
HIV-related aneurysms occur in young adults (under 45 
years) with advanced HIV infection (CD4 count less than 
200 cells/µl). Patients are generally HAART-naïve. There is 
some evidence that HAART to an extent improves the clini-
cal course of HIV-related aneurysms in paediatric patients. 
Whether HAART will influence outcomes in HIV-related 
aneurysms in adults is still to be defined. Novel endovascular 
strategies are now available to treat selected individuals. 
HIV and cerebral venous thrombosis 
This is a rare manifestation in HIV-infected patients. 
Meyohas et al. reported a case of superior saggittal sinus 
(SSS) thrombosis in a patient with dual primary infec-
tion with HIV and CMV, both viruses known to be associ-
ated with vasculitis.32 The thrombophilia screen was normal. 
Prendki et al. reported SSS and transverse sinus (TS) throm-
bosis in 2 HIV-infected patients as part of a rapid immune 
reconstitution inflammatory syndrome (IRIS).33 Both 
patients were initially treated for cryptococcal meningitis. 
One patient subsequently had his HAART regimen revised, 
while HAART was commenced in the second patient. Both 
patients developed progressive neurological symptoms follow-
ing a delay of 1 - 2 months of HAART. MR imaging revealed 
SSS and TS thrombosis in both patients. Anticoagulation was 
instituted with variable clinical response.
Cardiovascular disease
Common cardiovascular manifestations in HIV-infected 
individuals include pericardial effusions, myocarditis, dilated 
cardiomyopathy, systemic hypertension (up to 74% of HIV-
infected patients in the HAART era), HIV-associated pulmo-
nary hypertension and AIDS-related cardiac tumours.34,35
HIV and coronary vasculitis 
A wide variety of vasculitides unrelated to HIV may affect the 
coronary arteries, including polyarteritis nodosa, Henoch-
Schönlein purpura and drug-induced vasculitis.35,36 Shingadia 
et al. reported a case of Takayasu`s disease in an HIV-infected 
adolescent.37
Kawasaki-like syndromes have also been reported.5,38 
Kawasaki disease is an acute vasculitic syndrome of unknown 
aetiology occurring in paediatric patients under 5 years 
of age. The diagnosis is based on clinical features includ-
Fig. 2. Vertebral digital subtraction angiogram after coiling 
(arrow) showing occlusion of side-branch false aneurysms and 
recanalised vertebral artery. (Courtesy Professor Allan Taylor, 
Division of Neurosurgery, University of Cape Town.)
Fig. 1a.  Axial view of magnetic resonance angiogram showing 
multiple irregular central cerebral artery stenoses and 
dilatations (arrows). (Courtesy Professor Allan Taylor, Division 
of Neurosurgery, University of Cape Town.)
Fig. 1b. Lateral common carotid artery digital subtraction 
angiogram showing multifocal central cerebral artery irregular 
stenoses and dilatations (arrows). (Courtesy Professor Allan 
Taylor, Division of Neurosurgery, University of Cape Town.)
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ing fever of over 5 days, bilateral conjunctivitis, erythema 
or swelling of the hands and feet, rash, strawberry tongue 
and cervical lymphadenitis (lymph nodes greater than 15 
mm/non-infectious). Kawasaki disease typically affects small 
and medium-sized vessels, particularly the coronary arteries. 
Treatment consists of aspirin and intravenous immunoglobu-
lin. Coronary aneurysms developed in 24.6% (146/594) 
of paediatric patients in 1 large series.39  In the acute stage 
giant aneurysms (over 8 mm in diameter) were seen in 26 
patients with conventional angiography. Twelve progressed 
to stenosis or complete obstruction of the coronary arteries. 
Myocardial infarction occurred in 8 patients, with 4 deaths. 
Barbaro et al. reported a 32-year-old HIV-infected patient 
who presented with a myocardial infarct following a flu-like 
illness 1 week earlier.40 He had no other cardiovascular risk 
factors. His CD4 count was 230 cells/µl. Autopsy specimens 
of the coronary arteries revealed erosion and fissuring of 
the anterior descending and circumflex arteries. Histology 
revealed a dense lymphocytic infiltrate with necrosis of the 
intima. In situ hybridisation indicated the presence of HIV-1 
in the arterial wall. A follow-up study5 showed the presence 
of IgA plasma cells within the vasculitic lesion, a feature 
apparently unique to paediatric Kawasaki disease. Stankovic 
et al., in a review of the literature, identified 20 HIV-infected 
patients (17 men) with a Kawasaki-like syndrome.38 Eighteen 
patients were on HAART. The majority of patients had low 
CD4 counts (mean CD4 count was 83 cells/µl). Prognosis 
was favourable with aspirin and intravenous immunoglobu-
lin. No coronary aneurysms were described owing to lack 
of coronary imaging in these cases. Interestingly, in a recent 
review of coronary aneurysms, HIV was not listed in the 
pathogenesis.41
HIV and atherosclerotic coronary artery 
disease
Cardiology publications have noted the increasing frequency 
of coronary artery disease (CAD) in HIV-infected patients 
on HAART.42 There is still considerable debate regarding the 
exact aetiology of HIV-related CAD which may be due to 
HIV, HAART or HAART-associated metabolic syndrome, 
or a combination thereof. There is agreement that overall 
HAART has considerably modified outcomes in HIV/AIDS, 
reducing opportunistic infection, improving life expectancy 
and quality of life. However, concerns have now been raised 
regarding premature or accelerated atherosclerotic cardiovas-
cular, cerebrovascular and peripheral arterial disease in the 
older HIV cohort on longstanding HAART.43
The pathogenesis of atherosclerotic CAD is likely to be 
multifactorial.44,45  The association between low CD4 counts 
and CAD has been inconsistent. The dysmetabolic profile of 
HAART regimens, especially protease inhibitor (PI) based 
therapies, with increased total cholesterol, increased low-den-
sity lipoprotein (LDL), hypertriglyceridaemia, insulin resis-
tance and lipoatrophy/dystrophy, has been implicated.46-49 
HIV-infected patients with classic risk factors for CAD (age, 
personal or family history, diabetes mellitus, smoking, hyper-
lipidaemia) on HAART may be at increased risk of CAD. 
Mehta et al., in a review of 129 HIV-infected patients with 
CAD (mean age of 42 years) found no correlation between 
CD4 count and CAD.50 Acute myocardial infarction (MI) 
was the initial clinical presentation in 77% of patients. Forty-
seven per cent of patients had triple vessel disease (18% had 
2 vessel and 35% had 1 vessel disease). In one study mortal-
ity associated with a first MI approached 24%.42 Of concern 
is the finding that as many as 69% of patients were less than 
50 years old.46,50
Coronary pathology in these patients has been reported 
as distinct (diffuse and circumferential intimal thickening, 
atherosclerotic plaques and unusual proliferation of smooth 
muscle with luminal protrusions). Some of these features are 
seen in transplant vasculopathy.51,52
Rickerts et al., in a retrospective analysis of the Frankfurt 
HIV Cohort Study, found a fourfold increase in the annual 
incidence of CAD after the commencement of HAART.53 
Klein et al. reported a coronary event rate of 5.5/1 000 
patient years in the HAART era, higher than that of a control 
group.54 While the relative risk of increase in CAD in HIV-
infected patients on HAART approaches 25% per annum, 
the absolute increase in these patients is small.46,55 
HIV and HAART have confounded classic cardiac risk 
evaluation and categorisation. Other models beyond the 
Framingham score are currently being evaluated.37 Surrogate 
markers for the detection of subclinical atherosclerotic CAD 
are being evaluated (including coronary artery calcium score, 
high sensitivity C-reactive protein (CRP) and carotid intima 
medial thickness).56-59
Medical therapy for atherosclerotic CAD in these patients 
is along currently established guidelines. Caution should be 
exercised in the prescription of pharmaceutical agents, espe-
cially lipid-lowering agents metabolised by the same pathway 
as PIs. Pravastatin, and to a lesser extent atorvastatin, is pre-
ferred to simvastatin and lovastatin.60 
In contradistinction to the large cardiology experience 
with percutaneous coronary intervention (PCI) in non-HIV 
patients, the experience with PCI in HIV-infected patients is 
limited.61-63 Treatment with percutaneous transluminal coro-
nary angioplasty (PTCA) and coronary stenting (CS) has 
been described, with promising early outcomes.
Intermediate outcomes with PCI have also been reported. 
Boccara et al. reviewed their experience with 20 HIV-infected 
patients with acute coronary syndrome.64 Initially 4 patients 
received thrombolysis, 2 patients underwent PTCA and 7 
had CS. The remainder of the patients were treated medical-
ly. At a mean follow-up of 38 months (range 2 - 72 months) 
18 cardiovascular events, including 1 death, occurred in 50% 
of patients. None of the patients with a previous PCI needed 
target vessel revascularisation (TVR). Two patients had CS 
and 3 patients had a coronary artery bypass graft (CABG). 
In a similar case-controlled study, Hsue et al. showed simi-
lar results.65 Matetzky et al. compared HIV-infected patients 
with acute MI with a non-HIV control group.66 At 15 months 
follow-up the HIV-infected group had a higher incidence 
of recurrent MI and TVR, independent of type of HAART 
regimen. Similar findings at 36-month mean follow-up were 
noted by Escaut et al.67
Boccara et al. evaluated the outcomes of PCI in 50 HIV-
infected patients and compared them with 50 non-HIV 
patients.68 The procedural success was 98% in each group. 
Mean follow-up was 625 days. Clinical restenosis, TVR, 
major adverse cardiovascular event (MACE)-free and MI 
rates were not significantly different between the groups.
CABG in HIV-patients has been reported in HIV-infected 
patients with or without HAART. Blyth et al. reviewed their 
experience with cardiopulmonary bypass in 49 HIV-infected, 
HAART-naïve patients for a range of indications (CABG in 
3).69 The perioperative mortality was 6%, with 34.7% mor-
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bidity. Evolving criteria for cardiac surgery in HIV-infected 
patients at this unit included a CD4 count of over 400 cells/µl 
and the absence of AIDS. Traciotis et al. performed 27 cases 
of CABG with no perioperative deaths in this subgroup.70 
Freedom from a composite endpoint of angina, death, MI, 
repeat revascularisation and congestive cardiac failure at 3 
years was 81%. Similar results were reported by Castillo et 
al.71 With a follow-up of 8.2 years, the long-term mortality 
was 10.8%. Results of a multicentre case-control study, com-
paring CABG in HIV-infected patients, with CABG in HIV-
negative patients have been published recently.72  Thirty-day 
outcomes (death, MI, stroke, mediastinitis, and reinterven-
tion) were similar in both groups. At follow-up (median: 42 
months) MACE was significantly higher in the HIV-infected 
group (42% v. 25%), predominantly due to the need for PCI 
of progressive occlusive disease in the native coronary arter-
ies (not graft related).
Visceral HIV-related vasculopathy
Vascular involvement of the mesenteric circulation in HIV-
infected individuals is not commonly described.
HIV and mesenteric vasculitis
Polyarteritis nodosa-like syndromes and nonspecific sys-
temic necrotising vasculitis are the commonest vasculitides 
described in HIV-infected individuals, typically involving 
skin, muscle and peripheral nerves.73  Reports of mesenteric 
or renal involvement are rare compared with classic polyar-
teritis nodosa (PAN). Coinfection with current hepatitis B in 
these cases is rarely described. Acute flare-ups are not seen in 
the HIV population.
Sambatakou et al. reported a case of acute mesenteric 
ischaemia in a 31-year-old HIV-infected, HAART-naïve 
patient (with CD4 count of 142 cells/µl and viral load 
of 217.400 copies/ml).74 Colonoscopy revealed rectal 
and sigmoid mucosal erosions. The patient underwent a 
laparotomy with resection of 125 cm of ileum. The diagnosis 
of mesenteric artery thrombosis was entertained at 
laparotomy. Histopathology revealed a necrotising vasculitis 
involving small and medium-sized vessels of the gut, with gut 
ulceration and ischaemia. A renal biopsy for progressive renal 
dysfunction revealed IgA deposits in the capillaries (a feature 
of PAN). He was treated with cyclophosphamide, prednisone 
and HAART and recovered well.
Cytomegalovirus (CMV) vasculitis occurs in immunocom-
promised individuals, causing colitis.75 However, descriptions 
of CMV colitis in HIV-infected individuals have not paral-
leled the HIV pandemic.
Acute mesenteric ischaemia has been documented as a 
complication of treatment.76  Zaraa et al. described acute 
mesenteric ischaemia in an HIV-infected 44-year-old woman 
with Kaposi`s sarcoma following treatment with interferon-
A2b and the development of the haemolytic uraemic syn-
drome. Rapid clinical improvement followed withdrawal of 
interferon.
HIV and chronic mesenteric ischaemia
Mesenteric large-vessel involvement is unusual in HIV-
infected individuals. A large case series profiling 92 HIV-
related aneurysms in 28 patients identified only 3 visceral 
aneurysms. All 3 were asymptomatic and always associated 
with aortic aneurysms. One coeliac artery aneurysm was 
thrombosed. There were 2 saccular aneurysms and 1 fusi-
form aneurysm.1,2
Chahid et al. reported a case series of 14 patients with 
chronic mesenteric ischaemia treated by percutaneous trans-
luminal angioplasty (PTA) with or without a stent.77 A 32- 
year-old female patient with antiphospholipid syndrome was 
HIV positive, with early-onset mesenteric atherosclerosis. 
She presented with weight loss and post-prandial pain. She 
underwent a PTA and stent with a good technical and clini-
cal outcome on follow-up.
Intraparenchymal splenic artery calcification in a branching 
configuration has been reported in HIV-infected paediatric 
patients.78  The significance of this finding remains obscure.
HIV and abdominal venous thrombosis 
Portal and splenic vein thrombosis has been rarely reported 
in HIV-infected individuals.79-81 Crum-Cianflone et al. evalu-
ated 465 HIV-infected patients for venous thrombosis  and 
found 17 patients (3.7%) with 19 thrombotic events.81 Two 
were located in the splenic and portal veins. All patients 
were on HAART. All had identifiable risk factors for venous 
thrombosis. In their review of the literature, they identified 
9 cases of portal vein thrombosis reported in HIV-infected 
individuals. The pathogenesis of venous thrombosis in HIV-
infected patients is probably multifactorial. Indinavir, a PI, 
has been associated with portal vein thrombosis.82
Renal HIV-related vasculopathy 
Renal manifestations of HIV include HIV-associated 
nephropathy (HIVAN), ‘collapsing glomerulopathy’, IgA glo-
merulonephritis, microangiopathic nephropathy (haemolytic 
uraemic syndrome), immune complex (systemic lupus-like) 
syndrome and mixed cryoglobulinaemic vasculitis.
There is a growing awareness of PAN-like syndromes in 
HIV-infected patients. PAN-like syndromes in HIV-infected 
individuals, although less common compared with classic 
PAN, can also involve the renal circulation. Sagcan et al. 
reported a 29-year-old HIV-positive patient who presented 
with spontaneous bilateral perirenal haematomas.83 A 
renal angiogram showed multiple intraparenchymal 
microaneurysms typical of PAN. A unilateral nephrectomy 
was performed and the diagnosis of PAN was confirmed on 
histology. 
Adjunctive treatment invariably includes azathioprine or 
cyclophosphamide, prednisone and HAART. Prognosis with 
bilateral spontaneous perirenal haematomas associated with 
PAN is reported to be poor, with 5 of 9 patients dying within 
6 months.84 Less invasive treatment strategies have evolved to 
treat ruptured intrarenal aneurysms, including transcatheter 
embolisation.
HIV-related large-vessel renal artery aneurysm or occlu-
sion is rare. Nair et al., in reviewing a large institutional series 
of HIV-related aneurysms, reported 1 patient with severe 
hypertension.1 The 18-year-old patient was found to have 
a large suprarenal abdominal aortic aneurysm (AAA) with 
renal involvement and a non-functioning right kidney. She 
was treated by elective repair of the suprarenal AAA with 
multiple side-arm grafting to the visceral and left renal arter-
ies. A right nephrectomy was performed. Unfortunately the 
patient died following acute renal failure secondary to occlu-
sion of the graft to the left renal artery.
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Conclusion
Vasculitides, although uncommon in HIV-infected indi-
viduals, should trigger an exhaustive screen for other aetiol-
ogy (including co-infections, lymphoproliferative disease, and 
autoimmune disorders) before ascribing it to HIV. Whether 
HAART will alter the incidence of these vasculitides, and the 
outcomes associated with some of the manifestations, includ-
ing intracranial aneurysms, remains speculative. Whether an 
increased roll-out of HAART in less-developed countries will 
translate into a delayed increased risk of atherosclerotic vas-
cular disease, as expressed in developed countries, remains 
to be defined. HAART has affected conventional medical 
management guidelines for established atherosclerotic vas-
cular disease, especially lipid management, in HIV-infected 
patients, and these adjustments should be incorporated in 
our current management of these patients.
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